Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Muscle Invasive Bladder Neoplasms: full-pipeline trial registry
6 of 7 indexed Non-Muscle Invasive Bladder Neoplasms trials are currently recruiting.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Non-Muscle Invasive Bladder Neoplasms: 7 US clinical trials tracked, 6 recruiting.
Non-Muscle Invasive Bladder Neoplasms is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 5 of these trials.
Enrollment posture brief
Registry condition non-muscle-invasive-bladder-neoplasms
OPEN 6 | RECR 86% | LATE 3 | EARLY 3 | RANK #2497 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)
Non-Muscle Invasive Bladder Neoplasms lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Muscle Invasive Bladder Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Muscle Invasive Bladder Neoplasms is recruiting above its size-band peers.
6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-Muscle Invasive Bladder Neoplasms research.
Janssen Research & Development accounts for 5 of 7 trials (71.4%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Muscle Invasive Bladder Neoplasms enrolment sits around 235 participants.
Median target enrolment is 235 among the 7 trials that report a genuine target (sentinel values excluded). 1 of those (14.3%) plan for fewer than 100 participants.
-
Non-Muscle Invasive Bladder Neoplasms research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Janssen Research & Development
NCT06319820
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Merck Sharp & Dohme
NCT06833073
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development
NCT05316155
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Janssen Research & Development
NCT06919965
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Janssen Research & Development
NCT07309445
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT05483868
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Janssen Research & Development
NCT06211764
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Muscle Invasive Bladder Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Muscle Invasive Bladder Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Muscle Invasive Bladder Neoplasms page
7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Non-Muscle Invasive Bladder Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Non-Muscle Invasive Bladder Neoplasms trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Muscle Invasive Bladder Neoplasms condition card totals 7 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.